Fig. 7: XIST attenuated myocardial pyroptosis by activating miR-214-3p-mediated Arl2 in AF. | Laboratory Investigation

Fig. 7: XIST attenuated myocardial pyroptosis by activating miR-214-3p-mediated Arl2 in AF.

From: LncRNA XIST shuttled by adipose tissue-derived mesenchymal stem cell-derived extracellular vesicles suppresses myocardial pyroptosis in atrial fibrillation by disrupting miR-214-3p-mediated Arl2 inhibition

Fig. 7: XIST attenuated myocardial pyroptosis by activating miR-214-3p-mediated Arl2 in AF.

A qRT-PCR analysis of miR-214-3p, XIST, and Arl2 in HL-1 cells upon treatment with XIST EVs, sh-Arl2, miR-214-3p, or NC EVs. B Western blot analysis of XIST, and Arl2 in HL-1 cells upon treatment with XIST EVs, sh-Arl2, miR-214-3p, or NC EVs. C qRT-PCR analysis of NLRP3, ASC, caspase-1, and GSDMD in HL-1 cells upon treatment with XIST EVs, miR-214-3p, sh-Arl2, or NC EVs. D Western blot analysis of NLRP3, ASC, cleaved-caspase-1/caspase-1, and GSDMD in HL-1 cells upon treatment with XIST EVs, sh-Arl2, miR-214-3p, or NC EVs and corresponding quantification. E ELISA of IL-1β and IL-18 in HL-1 cells upon treatment with XIST EVs, sh-Arl2, miR-214-3p, or NC EVs. F Immunocytochemical staining of NLRP3, caspase-1, and IL-1β in HL-1 cells upon treatment with XIST EVs, miR-sh-Arl2, miR-214-3p, or NC EVs. G Representative images of Ki67 immunofluorescence staining of atrial tissues upon treatment with XIST EVs, sh-Arl2, miR-214-3p, or NC EVs. *p < 0.05 versus mice receiving AF, XIST EVs, and NC; #p < 0.05 versus mice receiving AF, XIST EVs, and sh-NC by one-way ANOVA with Tukey’s post hoc test, n = 12 per group. Error bars indicate mean ± standard deviation.

Back to article page